Invisio currently has a number of product opportunities available for partnering.

Currently Invisio Pharma is generating a portfolio of products at a variety of stages of development. We focus on New Therapeutic Entities – products that have already been approved but can be re-profiled – improved products to fulfil a strong patient need. This allows us to focus on dynamic and fast development timelines, requiring small investments of time and funding to reach commercialisation. At present we are focussing on:

A Potent Anti-depressant effective on all symptoms of depression including depresses libido (available for European approval and marketing).

A Once Weekly Oral Tablet anti-psychotic for improved adherence to therapy over once daily oral treatment.

A transdermal/transbuccal invisible spray-on patch therapy for a variety of CNS conditions including Alzheimers, Parkinsons, ADHD, Migraine, Epilepsy….

All these products are available for partial or full funding, joint venture activity or out-licensing.